Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 12 | 2024 | 2347 | 1.640 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 9 | 2024 | 1114 | 1.480 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2023 | 77 | 0.880 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 164 | 0.870 |
Why?
|
| Maxillary Sinus Neoplasms | 1 | 2022 | 8 | 0.850 |
Why?
|
| Venous Thrombosis | 2 | 2022 | 250 | 0.840 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 31 | 0.830 |
Why?
|
| Paranasal Sinuses | 1 | 2022 | 60 | 0.810 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 332 | 0.700 |
Why?
|
| Neoadjuvant Therapy | 2 | 2022 | 373 | 0.700 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 281 | 0.690 |
Why?
|
| Heparin | 1 | 2020 | 185 | 0.650 |
Why?
|
| Carcinoma | 1 | 2022 | 443 | 0.650 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 187 | 0.640 |
Why?
|
| Melanoma | 1 | 2022 | 467 | 0.610 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2022 | 2657 | 0.590 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 2411 | 0.530 |
Why?
|
| Porphyria Cutanea Tarda | 1 | 2015 | 1 | 0.530 |
Why?
|
| Holoprosencephaly | 1 | 2015 | 11 | 0.520 |
Why?
|
| Mutation | 2 | 2024 | 4132 | 0.510 |
Why?
|
| Drug Eruptions | 1 | 2015 | 34 | 0.510 |
Why?
|
| Skin Diseases, Infectious | 1 | 2014 | 13 | 0.490 |
Why?
|
| Soft Tissue Infections | 1 | 2014 | 26 | 0.480 |
Why?
|
| Humans | 38 | 2024 | 89063 | 0.480 |
Why?
|
| Immunotherapy | 5 | 2023 | 669 | 0.470 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 1363 | 0.470 |
Why?
|
| Sarcoma, Myeloid | 1 | 2014 | 15 | 0.460 |
Why?
|
| Anthropometry | 1 | 2013 | 75 | 0.450 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 415 | 0.450 |
Why?
|
| Leprosy | 1 | 2012 | 8 | 0.420 |
Why?
|
| Gestational Age | 1 | 2013 | 323 | 0.420 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 1239 | 0.410 |
Why?
|
| Infant, Premature | 1 | 2013 | 295 | 0.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 2552 | 0.390 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 395 | 0.380 |
Why?
|
| Lung | 1 | 2017 | 1258 | 0.380 |
Why?
|
| Periodicals as Topic | 1 | 2013 | 168 | 0.370 |
Why?
|
| Terminal Care | 1 | 2012 | 137 | 0.370 |
Why?
|
| Health Care Costs | 1 | 2012 | 235 | 0.360 |
Why?
|
| Venous Thromboembolism | 2 | 2023 | 159 | 0.360 |
Why?
|
| Neoplasms | 2 | 2022 | 3035 | 0.350 |
Why?
|
| Granuloma | 2 | 2021 | 65 | 0.350 |
Why?
|
| Psoriasis | 1 | 2012 | 245 | 0.340 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 3000 | 0.320 |
Why?
|
| Students, Medical | 1 | 2013 | 418 | 0.300 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2014 | 788 | 0.290 |
Why?
|
| Hypertension | 2 | 2023 | 741 | 0.280 |
Why?
|
| Glioblastoma | 2 | 2019 | 265 | 0.270 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 1063 | 0.250 |
Why?
|
| Female | 17 | 2023 | 46011 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2022 | 1096 | 0.230 |
Why?
|
| Retrospective Studies | 8 | 2022 | 9003 | 0.230 |
Why?
|
| Prognosis | 7 | 2021 | 3773 | 0.230 |
Why?
|
| India | 2 | 2014 | 123 | 0.230 |
Why?
|
| Male | 17 | 2020 | 42251 | 0.230 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2022 | 12 | 0.210 |
Why?
|
| Brain Neoplasms | 2 | 2019 | 781 | 0.210 |
Why?
|
| Biomarkers, Tumor | 2 | 2022 | 1543 | 0.210 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 172 | 0.210 |
Why?
|
| Nasal Cavity | 1 | 2022 | 91 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 1 | 2024 | 285 | 0.200 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 1706 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2022 | 3443 | 0.190 |
Why?
|
| Adult | 11 | 2021 | 26507 | 0.190 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 1194 | 0.180 |
Why?
|
| Middle Aged | 12 | 2020 | 25863 | 0.180 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 1591 | 0.180 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 273 | 0.180 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 6777 | 0.180 |
Why?
|
| Infant, Newborn | 3 | 2015 | 2476 | 0.170 |
Why?
|
| Aged | 11 | 2020 | 19077 | 0.170 |
Why?
|
| Cerebrum | 1 | 2019 | 16 | 0.170 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 573 | 0.170 |
Why?
|
| Endocarditis, Bacterial | 1 | 2019 | 38 | 0.160 |
Why?
|
| Pulmonary Valve | 1 | 2019 | 34 | 0.160 |
Why?
|
| Young Adult | 4 | 2020 | 6288 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 131 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 485 | 0.160 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 170 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2022 | 8203 | 0.150 |
Why?
|
| Neuroimaging | 1 | 2018 | 117 | 0.150 |
Why?
|
| Pneumonectomy | 1 | 2020 | 206 | 0.150 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2018 | 139 | 0.150 |
Why?
|
| Radiation Injuries | 1 | 2018 | 160 | 0.150 |
Why?
|
| Contrast Media | 1 | 2022 | 1090 | 0.150 |
Why?
|
| Oncogene Fusion | 1 | 2017 | 9 | 0.140 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2017 | 10 | 0.140 |
Why?
|
| Reference Standards | 1 | 2017 | 144 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2017 | 23 | 0.140 |
Why?
|
| Crack Cocaine | 1 | 2016 | 3 | 0.140 |
Why?
|
| Burns, Chemical | 1 | 2016 | 12 | 0.140 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 309 | 0.140 |
Why?
|
| beta-Thalassemia | 1 | 2016 | 6 | 0.140 |
Why?
|
| Laryngeal Diseases | 1 | 2016 | 21 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2018 | 269 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2016 | 45 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 763 | 0.130 |
Why?
|
| Cocaine-Related Disorders | 1 | 2016 | 36 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 981 | 0.130 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 469 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2016 | 166 | 0.130 |
Why?
|
| Cell Nucleus | 1 | 2017 | 599 | 0.130 |
Why?
|
| Child | 3 | 2016 | 7149 | 0.120 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2014 | 26 | 0.120 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2018 | 595 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 738 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2014 | 64 | 0.120 |
Why?
|
| Social Class | 1 | 2014 | 135 | 0.120 |
Why?
|
| Prostate | 1 | 2017 | 393 | 0.120 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2013 | 31 | 0.110 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 78 | 0.110 |
Why?
|
| Birth Weight | 1 | 2013 | 145 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 479 | 0.110 |
Why?
|
| Software | 1 | 2017 | 665 | 0.110 |
Why?
|
| Peer Review | 1 | 2013 | 23 | 0.110 |
Why?
|
| Clobetasol | 1 | 2012 | 3 | 0.110 |
Why?
|
| Terminally Ill | 1 | 2012 | 23 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 582 | 0.100 |
Why?
|
| Pain | 1 | 2013 | 400 | 0.090 |
Why?
|
| Glucose | 1 | 2013 | 630 | 0.090 |
Why?
|
| Education, Medical | 1 | 2013 | 243 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 345 | 0.090 |
Why?
|
| Algorithms | 1 | 2017 | 1875 | 0.080 |
Why?
|
| Support Vector Machine | 2 | 2018 | 25 | 0.080 |
Why?
|
| Infant | 1 | 2015 | 3147 | 0.080 |
Why?
|
| Adolescent | 3 | 2018 | 9237 | 0.080 |
Why?
|
| Quality of Life | 1 | 2016 | 1662 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2019 | 2863 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2752 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 1768 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 859 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 848 | 0.070 |
Why?
|
| Survival Rate | 2 | 2020 | 1889 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3657 | 0.060 |
Why?
|
| Ribose | 1 | 2023 | 17 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 2001 | 0.050 |
Why?
|
| Succinate Dehydrogenase | 1 | 2022 | 17 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 51 | 0.050 |
Why?
|
| Paraganglioma | 1 | 2022 | 16 | 0.050 |
Why?
|
| Bevacizumab | 1 | 2023 | 287 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2023 | 561 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 142 | 0.050 |
Why?
|
| United States | 1 | 2012 | 6955 | 0.040 |
Why?
|
| Dental Prophylaxis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Streptococcus mitis | 1 | 2019 | 2 | 0.040 |
Why?
|
| Radiometry | 1 | 2019 | 56 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2019 | 56 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 459 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 257 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 410 | 0.040 |
Why?
|
| Animals | 1 | 2017 | 27317 | 0.040 |
Why?
|
| Discriminant Analysis | 1 | 2017 | 67 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 127 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2017 | 43 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2017 | 337 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 779 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2016 | 190 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 372 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 359 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1533 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 576 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 781 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1214 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 685 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1108 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1715 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1488 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2017 | 476 | 0.030 |
Why?
|
| Crying | 1 | 2013 | 6 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 937 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1429 | 0.030 |
Why?
|
| Social Behavior | 1 | 2016 | 299 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2013 | 328 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 682 | 0.030 |
Why?
|
| Age Factors | 1 | 2016 | 1867 | 0.020 |
Why?
|
| Heart Rate | 1 | 2013 | 493 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1714 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 3717 | 0.020 |
Why?
|
| Oxygen | 1 | 2013 | 742 | 0.020 |
Why?
|
| Risk Factors | 1 | 2017 | 5466 | 0.020 |
Why?
|